1. Introduction
===============

Colorectal cancer (CRC) is the third most common cancer in the world and ranks as 1 of the 5 most common fatal cancers worldwide.^\[[@R1]\]^ Increasing evidence indicates that gut microbiota play various roles in carcinogenesis, prognosis, and treatment response of CRC.^\[[@R2],[@R3]\]^ Among these gut microbiota, *Fusobacterium nucleatum* has been found to be significantly elevated in tumor tissues and stool specimens of CRC patients relative to those in normal controls.^\[[@R4],[@R5]\]^ In addition, the amount of invasive *F nucleatum* gradually increases from premalignant adenomatous lesions to carcinomas in the colorectal carcinogenesis pathway.^\[[@R6],[@R7]\]^ There have been many studies investigating the mechanism of *F nucleatum* instigating and potentiating colorectal tumor by using tumor tissues. It has been reported that the accumulation of *F nucleatum* in colorectal tumor is partly due to fusobacterial lectin Fap 2^\[[@R8]\]^ and Fad A adhesion,^\[[@R2]\]^ and that *F nucleatum* can induce the carcinogenesis and development of colorectal tumor by the microRNA-21-mediated pathway^\[[@R9]\]^ or inhibition of host adaptive immunity,^\[[@R10],[@R11]\]^ and so on.

However, there were also some studies producing conflicting results.^\[[@R12],[@R13]\]^ The diagnostic and prognostic characteristics of *F nucleatum* for CRC have been ambiguous, with sensitivity ranging from 45% to 100%, and specificity ranging from 10% to 92%.^\[[@R14],[@R15]\]^ To explore the effect of *F nucleatum* load on prognosis of patients with CRC, we designed a study to investigate the relationships between *F nucleatum*, and clinicopathological features and molecular factors (including kirsten rat sarcoma viral oncogene (KRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), and microsatellite instability \[MSI\]).

2. Materials and methods
========================

2.1. Clinical and pathological data
-----------------------------------

From January, 2017 to January, 2019, 91 patients with stage III or high-risk stage II CRC were subjected to thorough history taking and clinical examination, and their clinical and pathological information was collected from the database of Wuhan Union Hospital in China. Age, sex, tumor location, and gross tumor type, pT/pN categories, tumor grade, lymphovascular invasion, perineural invasion were identified from the patient medical reports. This study protocol was approved by the ethics committee of our college. All patients signed an informed consent regarding their understanding of the procedure and its potential complications, and also their approval of participation in the research. All participating subjects were fully informed of the study and the associated risks before signing an informed consent form, and the principles outlined by the Declaration of Helsinki (2013) were adopted in this study.

2.2. Inclusion and exclusion criteria
-------------------------------------

The inclusion criteria for the case selection were age greater than 18 years, adenocarcinoma histology without neuroendocrine or squamous cell component, stage III or high-risk stage II according to pathological staging, complete resection (R0) of the primary tumor with tumor-free resection margins, and the completion of at least 6 cycles of adjuvant Calcium Folinate Fluorouracil OXaliplatin chemotherapy or 4 cycles of adjuvant Capecitabine and Oxaliplatin therapy. The criteria for high-risk stage II were tumor invasion into visceral peritoneum or direct invasion into adjacent organ structures (pT4), clinical obstruction or perforation, poorly differentiated or undifferentiated histology (G3/G4), lymphovascular invasion, and perineural invasion. The patients who received preoperative neoadjuvant chemotherapy and/or radiotherapy (especially patients with rectal cancer) and patients with a history of other malignancy within 5 years were excluded.

2.3. DNA extraction and mutation analysis
-----------------------------------------

Tumor DNAs were extracted from formalin-fixed, paraffin-embedded (FFPE) tissues containing more than 50% tumor cells using the QIAamp DNA Mini Kit (Qiagen). Detection of KRAS exon 2 hotspot mutations and BRAF V600E mutations was performed.

2.4. Quantitative PCR for *F nucleatum*
---------------------------------------

Genomic DNA extraction from FFPE tissues of the 91 CRCs and quantitative polymerase chain reaction (qPCR) for *F nucleatum*, using a commercial QIAmp DNA Mini Kit (QIAGEN, Hilden, Germany), according to the manufacturer\'s instructions. DNA was stored at −80°C, until use. DNA amplification was performed in a final volume of 20 μL (SYBR Premix EX Taq II \[2X\] \[TLi RNaseH Plus\]), 20 pmol of forward and reverse primers, and 2 μL of extracted DNA with ABI 7500 (Applied Biosystem). The thermo cycling program was as follows: 35 cycles of 95°C for 5 seconds and 60°C for 34 seconds with an initial cycle of 95°C for 10 minutes, and a primer pair-specific annealing temperature for 60 seconds. A melting curve was used to evaluate the presence of primers-dimers. In brief, the following primers and probes targeting the 16S rRNA gene DNA sequence of *F nucleatum* and the reference gene (prostaglandin transporter \[PGT\]) were used: *F nucleatum* forward primer, 5'-CAACCATTACTTTAACTCTACCATG-TTCA-3'; *F nucleatum* reverse' primer, 5'-GTTGACTTTACAG-AAGGAGATTATGTAAAAATC-3'; *F nucleatum* FAM probe, 5'-GTTGACTTTACAGAAGGAGATTA-3'; PGT forward primer, 5'-ATCCCC AAAGCACCTGGTT-T-3'; PGT reverse primer, 5'-AGAGGCCAAGATAGTCCTGGTAA-3'; PGT VIC probe, 5'-CCATCCATGTC-CTCATCTC-3'. The PCR conditions were 95°C for 10 minutes followed by 45 cycles of 95°C for 15 seconds, and 60°C for 1 minute. To compare the *F nucleatum* DNA amounts between tumor DNA samples, the relative values (2^−ΔCt^) calculated from the threshold cycle (Ct) values for *F nucleatum* normalized to PGT were used. The qPCR method was validated using serially-diluted *F nucleatum* genomic DNA samples (25586D-5; ATCC, Manassas, VA). *F nucleatum*-positive CRCs were further classified into 2 subgroups (*F nucleatum*-high or *F nucleatum*-low) using a cut-off median value of 2^−ΔCt^.

2.5. Microsatellite status determination
----------------------------------------

Mismatch repair (MMR) tumor status was determined by immunohistochemistry (IHC) or by MSI testing when IHC was indeterminate in accordance of the Bethesda criteria and as previously described for each trial.^\[[@R16],[@R17]\]^ MSI phenotype tumors were defined as presenting with the loss of 1 or more MMR proteins' expression by IHC or exhibiting high-level tumor DNA MSI (MSI-H) on MSI testing. Microsatellite-stable phenotype tumors were defined by normal MMR protein expression in IHC, or MSS or low-level MSI (MSI-L) status on MSI testing.

2.6. Statistical analysis
-------------------------

All data were analyzed using the statistical package SPSS version 23.0. All measurement data were represented as (![](medi-98-e17221-i001.jpg) ± s). The paired *t* test was used in the group, and the analysis of variance was used in the group. The count data were expressed in percentage (%), and the data were processed by chi-square test, and *P* \< .05 was considered statistically significant. The Cox risk ratio model analysis was performed to identify independent risk factors of *F nucleatum*. *F nucleatum*-high group was compared with the *F nucleatum*-low/negative group with respect to clinicopathological features and their relationships with MSI status. Kaplan--Meier method and log-rank test were used for univariate analysis of prognostic factors in patients with CRC.

3. Results
==========

3.1. Baseline patient characteristics
-------------------------------------

We retrospectively analyzed the information of 91 patients hospitalized for CRC from January, 2017 to January, 2019. They are divided into 2 groups according to the *F nucleatum* status, *F nucleatum*-high 25 patients, and *F nucleatum*-low 66 patients. The qPCR for *F nucleatum* is shown in Fig. [1](#F1){ref-type="fig"}.

![The qPCR for *Fusobacterium nucleatum* in tumor. (A) *F nucleatum* CT; (B) melting curve.](medi-98-e17221-g001){#F1}

We compared the basic characteristics of the patients (age, sex, BMI), and the result showed that there is no statistical significance between the 2 groups (*P* = .298, *P* = .364, *P* = .638). The proportion of *F nucleatum*-high tumors was highest among descending colon cancers, whereas that of *F nucleatum*-high tumors was lowest among ascending colon cancers (36.0% and 13.3%, respectively) (Fig. [2](#F2){ref-type="fig"}). There were 3 cases of hypertension, 1 case of diabetes mellitus, and 1 case of hypertension with diabetes mellitus in *F nucleatum*-high group, whereas 5 cases of hypertension, 1 case of diabetes mellitus, 1 case of coronary heart disease, 1 case of diabetes mellitus, hypertension, and coronary heart disease, 1 case of cerebral infarction with coronary heart disease, 1 case of cirrhosis with hypertension, and 1 case of hypertension with coronary heart disease in *F nucleatum*-low group.

![Different proportions of *Fusobacterium nucleatum*-high versus *F nucleatum*-low colorectal cancers according to tumor sidedness.](medi-98-e17221-g002){#F2}

The relationship between clinicopathological and *F nucleatum* status showed that there were no significant differences in the location of tumors, the differentiation, T stage, N stage, and TNM stage (AJCC 7th edition) between the 2 groups (*P* = .549, *P* = .689, *P* = .066, *P* = .373, *P* = .64). However, the number of total lymph node acquisition and positive lymph nodes were higher in *F nucleatum*-high group (27.44 ± 25.213 vs 20.70 ± 10.141; *P* = .018; 3.80 ± 7.974 vs 1.74 ± 3.531; *P* = .001). Moreover, we found that nerve invasion and vascular tumor thrombus were more common in patients with *F nucleatum*-high (*P* = .003, *P* = .002). By analyzing the relationship between *F nucleatum* status and molecular characteristics, no significances were observed between *F nucleatum*, and KRAS and BRAF mutation, but microsatellite mutation was more frequent in *F nucleatum*-high group (84.0% vs 60.6%; *P* = .001) (Table [1](#T1){ref-type="table"}).

###### 

Characteristics of stage II/III CRCs according to the *Fusobacterium nucleatum* status.

![](medi-98-e17221-g003)

3.2. Survival prognostic factors
--------------------------------

Kaplan--Meier method and log-rank test were used for univariate analysis of prognostic factors in patients with CRC. There was significant difference in overall survival (OS) between the *F nucleatum*-high and *F nucleatum*-low/negative groups (log-rank *P* = .038) (Fig. [3](#F3){ref-type="fig"}). A higher abundance of *F nucleatum* in CRC is associated with a shorter survival time. The *F nucleatum* status, peripheral nerve invasion, vascular thrombus, lymph node metastasis, and TNM staging were related factors affecting the prognosis of patients with CRC (Table [2](#T2){ref-type="table"}). The Cox risk ratio model analysis showed that the *F nucleatum* (odds ratio \[OR\] 2.094, 95% confidence interval \[CI\] 1.178--8.122, *P* = .032) and MSI status (OR 2.243, 95% CI 1.136--5.865, *P* = .039) were independent prognostic factors in patients with CRC (Table [2](#T2){ref-type="table"}).

![Kaplan--Meier survival analysis. Statistical difference in overall survival was evident between *Fusobacterium nucleatum*-high and *Fusobacterium nucleatum*-low subgroups in the overall 91-stage colorectal cancer patients.](medi-98-e17221-g004){#F3}
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Univariate and multivariate analyses of prognostic factors in colorectal cancer.
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4. Discussion
=============

*Fusobacterium nucleatum* is a Gram-negative obligate anaerobe bacterium in the oral cavity and plays a role in several oral diseases, including periodontitis and gingivitis.^\[[@R12],[@R18]\]^ Recently, several studies have reported that the level of *F nucleatum* is significantly elevated in human colorectal adenomas and carcinomas compared with that in adjacent normal tissue.^\[[@R19],[@R20]\]^ It has been validated that MSI-H is not a predictive factor because it is not related with better survival in patients with stage II and III colon cancer with adjuvant chemotherapy.^\[[@R21],[@R22]\]^ We decided to investigate the relationships between *F nucleatum*, and clinicopathological features and molecular factors (including KRAS, BRAF, and MSI).

Microsatellites or short tandem repeats correspond to short sequences of bases (from 1 to 6 bases), which are repeated throughout coding and noncoding regions of the genome. In these regions, the DNA polymerase tends to make more mistakes during the DNA synthesis by inserting additional bases. MSI increases mutation rates coming from defects in the DNA MMR by 100 to 1000 times.^\[[@R23],[@R24]\]^ Approximately 15% of colorectal adenocarcinomas are associated with MSI: 2.5% coming from a genetic inheritance and 12.5% being a sporadic one.^\[[@R25]\]^ Sporadic MSI is caused by epigenetic silencing of the MLH1 promoter by methylation, which is associated with a somatic BRAF V600E mutation. Hereditary MSI commonly happens due to autosomal dominant mutations in MMR. Critical analysis of the best available evidence in the literature allows us to conclude that stage II and III colon cancer with MSI-H is associated with a statistically significant better disease-free survival and OS compared with stage II and III colon cancer with low microsatellite instability (MSI-L) or microsatellite stability.^\[[@R26],[@R27]\]^ The survival in untreated patients with stage II or III colorectal adenocarcinoma and MSI-H was better than that in untreated patients with stage II or III colorectal adenocarcinoma and MSS.^\[[@R28]\]^ In our study, the greater amount of *F nucleatum* has a significant association with MSI-L/MSS.

Previous data indicate that high intratumoral *F nucleatum* load might be associated with poor prognostic effect.^\[[@R19],[@R20]\]^ Some researchers have demonstrated that *F nucleatum* modulates the tumor immune microenvironment while promoting CRC development.^\[[@R29]\]^ Recently, it has been confirmed that biomarkers such as immune antibodies, miRNA, tumor-associated macrophages, and tumor-infiltrating T-cell subsets play a significant role in *F nucleatum*-associated CRC.^\[[@R30],[@R31]\]^ A previous study has shown that lymph node metastases are present in 52 out of 88 (59.1%) cases with a high abundance of *F nucleatum* and in 0 out of 13 (0%) subjects with a low abundance of *F nucleatum*, which indicates that a high abundance of *F nucleatum* is associated with CRC progression and metastasis.^\[[@R32]\]^ Some researchers have also reported that the load of *F nucleatum* DNA in CRC tissue is correlated with higher CRC-specific mortality and that *F nucleatum* DNA may serve as a potential poor prognostic biomarker.^\[[@R33]\]^ Fusobacterium was shown to be enriched in the mucosa-adherent microbiota and have the ability to adhere to and invade human epithelial and endothelial cells.^\[[@R34],[@R35]\]^ Recently, several researchers have suggested that *F nucleatum* is a pathogenic bacterium rather than a bacterium that promotes colorectal carcinogenesis.^\[[@R36]\]^

This study\'s limitations deserve commentary. First, the proportion of *F nucleatum*-positive cases in CRCs by qPCR analysis has been variable according to different investigations (8.6%--74%).^\[[@R36]\]^ In our results, *F nucleatum* DNA was detected in 25 out of 91 cases (27.5%). The reason for variability in the *F nucleatum*-positive rate in CRCs is unclear, but tissue quality might be a critical factor for this discrepancy. Recently, Lee et al^\[[@R19]\]^ found that the tissue fixation method could affect different results of *F nucleatum* qPCR analysis. Therefore, it can be inferred that *F nucleatum*-positive rate by qPCR method could be variable, depending on tissue fixation method and tissue storage time. Second, our study cohort was retrospectively collected. The results of the present analysis will hopefully lead to a prospective randomized study with the ultimate goal of a centralized national program for prognostic relevance of *F nucleatum* in CRCs and its relationships with MSI status.
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